Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Glaukos Corp has demonstrated robust growth potential, particularly in its Corneal Health segment, which is projected to expand by 9.4% in FY26, with increased momentum anticipated in the latter half of the fiscal year as reimbursement for Epioxa improves. The company's innovative iDose TR product has begun to see higher sales traction, with an impressive gross margin of 85.1% in 4Q25, surpassing market expectations and contributing to an increase in revenue estimates for FY26. Additionally, the strong performance of Glaukos's iStent platform, with an estimated growth of approximately 7% year-over-year, further solidifies the positive financial outlook for the company.

Bears say

Glaukos Corp demonstrated a mixed financial performance, with domestic glaucoma revenue of $86 million exceeding consensus estimates, but overall growth metrics showed signs of decline, with slower growth rates for both domestic and international revenues compared to previous quarters. The company faces challenges with its micro-invasive glaucoma surgery (MIGS) segment and anticipates lowering legacy glaucoma sales growth forecasts due to increasing market headwinds and competition, which may impact future revenue generation. Adjusted earnings per share (EPS) estimates for 2026 and 2027 have been significantly revised downward, indicating a more pessimistic outlook for profitability amid concerns regarding market dynamics and product adoption rates.

Glaukos (GKOS) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 13 analysts, Glaukos (GKOS) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $134.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $134.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.